Search - tctmd.com

Displaying 61 - 77 of 77

Sort: Relevancy | Date

News Conference News ACC 2014

CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks

L.A. McKeown

March 31, 2014

News Conference News ACC 2014

TAV-in-BAV: TAVR Achieves Positive Outcomes In Bicuspid Aortic Valve Disease

Jason Kahn

March 30, 2014

News Conference News ACC 2014

TAVR With the CoreValve Device Superior to Surgery at 1 Year

Yael L. Maxwell

March 29, 2014

News Conference News ACC 2014

Depth, Cusp Stretching Linked to Need for Pacemaker after TAVR

L.A. McKeown

March 29, 2014

News Conference News ACC 2013

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

L.A. McKeown

March 14, 2013

News Conference News ACC 2013

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

Yael L. Maxwell

March 11, 2013

News Conference News ACC 2013

German Valve Registry Shows Advantage of Surgery in Lower Risk Patients

L.A. McKeown

March 11, 2013

News Conference News ACC 2013

PARTNER II Cohort B Demonstrates Safety, Efficacy of Lower Profile TAVR Device

L.A. McKeown

March 09, 2013

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

Study Looks at Long-term Mortality Predictors in TAVR Patients

Jason Kahn

March 27, 2012

News Conference News ACC 2012

PARTNER: TAVR Remains as Effective as Surgery at 2 Years

March 26, 2012

News Conference News ACC 2012

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

March 24, 2012

Video

» Interview

Beyond the Data: ADAPT-TAVR

April 6, 2022

Video

» Conference Wrap-Up

ACC 2019: Sunday Wrap-Up with Drs. Gibson and Kirtane

March 17, 2019

Video

» Interview

ACC 2019: Self-Expanding Transcatheter or Surgical Aortic Valve Replacement in Patients at Low Risk of Surgical Mortality

March 18, 2019

Video

» Interview

ACC 2019: PARTNER 3 - Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients

March 18, 2019

Video

» Interview

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-Valve Replacement

May 4, 2022

Advertisement

CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks

TAV-in-BAV: TAVR Achieves Positive Outcomes In Bicuspid Aortic Valve Disease

TAVR With the CoreValve Device Superior to Surgery at 1 Year

Depth, Cusp Stretching Linked to Need for Pacemaker after TAVR

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

German Valve Registry Shows Advantage of Surgery in Lower Risk Patients

PARTNER II Cohort B Demonstrates Safety, Efficacy of Lower Profile TAVR Device

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Study Looks at Long-term Mortality Predictors in TAVR Patients

PARTNER: TAVR Remains as Effective as Surgery at 2 Years

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

Beyond the Data: ADAPT-TAVR

ACC 2019: Sunday Wrap-Up with Drs. Gibson and Kirtane

ACC 2019: Self-Expanding Transcatheter or Surgical Aortic Valve Replacement in Patients at Low Risk of Surgical Mortality

ACC 2019: PARTNER 3 - Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content